C
C. Courtinard
Researcher at University of Bordeaux
Publications - 30
Citations - 556
C. Courtinard is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Metastatic breast cancer & Breast cancer. The author has an hindex of 7, co-authored 24 publications receiving 293 citations. Previous affiliations of C. Courtinard include PSL Research University.
Papers
More filters
Journal ArticleDOI
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Elisa Gobbini,Monia Ezzalfani,Véronique Diéras,Thomas Bachelot,Etienne Brain,Marc Debled,William Jacot,Marie Ange Mouret-Reynier,Anthony Gonçalves,Florence Dalenc,Anne Patsouris,Jean Marc Ferrero,Christelle Levy,Veronique Lorgis,Laurence Vanlemmens,C. Lefeuvre-Plesse,Simone Mathoulin-Pélissier,Thierry Petit,Lionel Uwer,Christelle Jouannaud,Marianne Leheurteur,Magali Lacroix-Triki,Audrey Lardy Cleaud,Mathieu Robain,C. Courtinard,Christian Cailliot,David Pérol,Suzette Delaloge +27 more
TL;DR: The OS of MBC patients has slightly improved over the past decade, however, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.
Journal ArticleDOI
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Elise Deluche,Alison Antoine,Thomas Bachelot,Audrey Lardy-Cleaud,Véronique Diéras,Etienne Brain,Marc Debled,William Jacot,Marie Ange Mouret-Reynier,Anthony Gonçalves,Florence Dalenc,Anne Patsouris,Jean Marc Ferrero,Christelle Levy,Veronique Lorgis,Laurence Vanlemmens,C. Lefeuvre-Plesse,Simone Mathoulin-Pélissier,Thierry Petit,Lionel Uwer,Christelle Jouannaud,Marianne Leheurteur,Magali Lacroix-Triki,C. Courtinard,David Pérol,Mathieu Robain,Suzette Delaloge +26 more
TL;DR: The ESME program represents a unique large-scale real-life cohort on MBC and highlights important situations of high medical need within MBC patients.
Journal ArticleDOI
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
Suzette Delaloge,D. Perol,C. Courtinard,Etienne Brain,Bernard Asselain,Thomas Bachelot,Marc Debled,Véronique Diéras,M. Campone,Christine Levy,William Jacot,Veronique Lorgis,Corinne Veyret,Florence Dalenc,J-M Ferrero,L. Uwer,P. Kerbrat,A. Gonçalves,M.-A. Mouret-Reynier,Thierry Petit,Christelle Jouannaud,Laurence Vanlemmens,G. Chenuc,T. Guesmia,M. Robain,C. Cailliot +25 more
TL;DR: In this large-scale, real-life setting, patients with HER2-negative MBC who received paclitaxel plus bevacizumab as first-line chemotherapy had a significantly better OS and PFS than those receiving pac litaxel.
Journal ArticleDOI
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
E. Jacquet,Audrey Lardy-Cleaud,Barbara Pistilli,S. Franck,Pietrina Cottu,Suzette Delaloge,Marc Debled,L. Vanlemmens,Marianne Leheurteur,A.V. Guizard,Lilian Laborde,L. Uwer,William Jacot,Delphine Berchery,Isabelle Desmoulins,J-M Ferrero,Geneviève Perrocheau,C. Courtinard,Etienne Brain,Sylvie Chabaud,Mathieu Robain,Thomas Bachelot +21 more
TL;DR: In this large retrospective cohort of patients with AI-sensitive metastatic luminal BC, OS was similar, whether first-line treatment was chemotherapy or endocrine therapy, and endocrine Therapy should be the first choice for first- line systemic treatment for MBC in the absence of visceral crisis.
Journal ArticleDOI
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Thomas Grinda,Alison Antoine,William Jacot,C. Blaye,Paul-Henri Cottu,Véronique Diéras,Florence Dalenc,A. Gonçalves,Marc Debled,Anne Patsouris,M.-A. Mouret-Reynier,Audrey Mailliez,Florian Clatot,C. Levy,J-M Ferrero,Isabelle Desmoulins,Lionel Uwer,Thierry Petit,Christelle Jouannaud,Magali Lacroix-Triki,Elise Deluche,M. Robain,C. Courtinard,Thomas Bachelot,Etienne Brain,D. Perol,Suzette Delaloge +26 more
TL;DR: The ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated their treatment in 18 French Cancer Centres since 2008 as discussed by the authors.